

Drug Use Review (DUR) Board approves changes effective March 3, 2025

The Nevada Medicaid Drug Use Review (DUR) Board met on July 18, 2024 and January 16, 2025 and voted to adopt the following changes to Pharmacy Point-of-Sale (POS) criteria, effective March 3, 2025.

| Drug Class/Program | Background and Explanation of Policy Changes, Clarifications and Updates |
|----------------------------------|---|
| Respirator and Allergy Biologics | <ul style="list-style-type: none">• Added new section “Fasenra® for treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA)”• Added new section “Dupixent® for treatment of Chronic Obstructive Pulmonary Disease (COPD)”• Added new section “Tezspire™”• Added new section “Adbry®” |

Prior Authorization forms may be found on the pharmacy webpage:
<https://nv.primetherapeutics.com/provider/forms> (pharmacy/point-of-sale)